Aspirin v placebo for primary prevention of cardiovascular disease in women*
| Outcomes at mean 10 years | Aspirin | Placebo | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| *Abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated from data in article. | ||||
| †Major cardiovascular event = non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes. | ||||
| Major cardiovascular event† | 2.4% | 2.6% | 9% (−3 to 20) | Not significant |
| Stroke | 1.1% | 1.3% | 17% (1 to 31) | 445 (227 to 10377) |
| Death from cardiovascular causes | 0.60% | 0.63% | 5% (−22 to 26) | Not significant |
| Transient ischemic attack | 0.93% | 1.2% | 22% (6 to 36) | 385 (216 to 1687) |
| RRI (CI) | NNH | |||
| Fatal or non-fatal myocardial infarction | 0.99% | 0.97% | 2% (−16 to 25) | Not significant |
| Gastrointestinal bleeding requiring transfusion | 0.6% | 0.5% | 40% (7 to 83) | 554 (305 to 2751) |
